Skip to main content

6 Result(s)

within J Walewski Remove this filter Oncology Remove this filter

and

  1. No Access

    Article

    Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials

    E Hoster, C H Geisler, J Doorduijn, B van der Holt, J Walewski, J Bloehdorn… in Leukemia (2016)

  2. No Access

    Article

    Presence of t(14;18) positive cells in blood and bone marrow does not predict outcome in follicular lymphoma

    Follicular Lymphoma International Prognostic Index—FLIPI is an established clinical predictor for outcome in follicular lymphoma. The role of molecular abnormalities in blood and bone marrow of follicular lymp...

    E. Paszkiewicz-Kozik, J. Kulik, A. Fabisiewicz, A. Tysarowski… in Medical Oncology (2009)

  3. No Access

    Article

    Rituximab (Mabthera™, rituxan™) in patients with recurrent indolent lymphoma

    The objective of this multiinstitutional study was to evaluate the safety and efficacy of rituximab at standard four weekly doses in patients with recurrent indolent lymphoma. Thirty-eight patients entered int...

    J. Walewski, E. Kraszewska, O. Mioduszewska, J. Romejko-Jarosińska… in Medical Oncology (2001)

  4. No Access

    Article

    CN3OP: an active regimen in patients with relapsed/refractory Hodgkin's lymphoma

    Patients with recurrent or refractory Hodgkin's and non-Hodgkin's lymphoma are increasingly being treated with high-dose therapy and hematopoietic cell transplantation. As minimal disease status at the time of...

    J Walewski, JB Krzyżanowska, E Kraszewska, E Lampka… in Medical Oncology (2000)

  5. No Access

    Chapter and Conference Paper

    Evaluation of In Vivo Natural Killer and Lymphokine-Activated Killer Cell Activity in Patients Treated with High-Dose Interleukin-2 and Adoptive Transfer of Autologous LAK Cells

    A substantial number of Phase I and Phase II clinical trials of interleukin-2 (IL-2) alone or combined with adoptive transfer of lymphokine-activated killer (LAK) cells in the treatment of cancer patients had ...

    J. Walewski, E. Paietta, J. Dutcher… in Cytokines in Hemopoiesis, Oncology, and AI… (1990)

  6. No Access

    Article

    Evaluation of natural killer and lymphokine-activated killer (LAK) cell activity in vivo in patients treated with high-dose interleukin-2 and adoptive transfer of autologous LAK cells

    This study investigated the development of peripheral blood natural killer (NK) and lymphokineactivated killer (LAK) cell activity in vivo in cancer patients treated with high doses of recombinant interleukin-...

    J. Walewski, E. Paietta, J. Dutcher… in Journal of Cancer Research and Clinical On… (1989)